The Danish Health Authority intends to wait until the Danish investigation of the Astrazeneca vaccine and possibly related rare cases of blood clots has been concluded before deciding whether Denmark will go back to using this particular vaccine, according to a press statement from the Danish Health Authority.
This announcement arrives in the wake of the European Medicines Agency (EMA) judging on Wednesday that the vaccine and certain rare cases of blood clots might be connected, but that the vaccine should still be put to use.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.